Advertisement

Drug Safety

, Volume 9, Issue 2, pp 85–92 | Cite as

The Current Role of 2,3-Dimercaptosuccinic Acid (DMSA) in the Management of Childhood Lead Poisoning

  • Deborah E. Glotzer
Commentary

Summary

2,3-Dimercaptosuccinic acid (DMSA) is an orally active chelating agent used in the treatment of lead and other heavy metal poisonings. In animals, DMSA chelates lead from soft tissues, including the brain, without clinically evident adverse effects or histopathological changes. In lead-poisoned children and adults, DMSA significantly increases urinary lead excretion, and, at least transiently, reduces the blood lead concentration. The safety profile of DMSA in both children and adults is encouraging, with few clinically apparent or biochemical adverse effects reported. However, clinical experience with DMSA is limited, and is not sufficient to exclude the possibility that other more serious drug-related adverse events including hypersensitivity or idiosyncratic reactions may occur. No data currently exist to determine whether drug-enhanced lead excretion with DMSA (or any other chelating agent) is beneficial in reducing lead-related neurotoxicity. The efficacy of DMSA in reducing neuropsychological morbidity, and additional safety data, are key areas requiring additional study before DMSA can be clearly recommended as the chelating agent of choice for the treatment of lead-poisoned children.

Keywords

DMSA Lead Poisoning DMPS Blood Lead Concentration Heavy Metal Poisoning 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aposhian HV. Biological chelation: 2,3-dimercaptopropanesulfonic acid and meso-dimercaptosuccinic acid. Advances in Enzyme Regulation 20: 301–319, 1982PubMedCrossRefGoogle Scholar
  2. Aposhian HV. DMSA and DMPS — water soluble antidotes for heavy metal poisoning. Annual Review of Pharmacology and Toxicology 23: 193–215, 1983PubMedCrossRefGoogle Scholar
  3. Aposhian HV, Maiorino RM, Dart RC, Perry DF. Urinary excretion of meso-2,3-dimercaptosuccinic acid in human subjects. Clinical Pharmacology and Therapeutics 45: 520–526, 1989PubMedCrossRefGoogle Scholar
  4. Aronson AL, Hammond PB. Effect of two chelating agents on the distribution and excretion of lead. Journal of Pharmacology and Experimental Therapeutics 146: 241–251, 1964PubMedGoogle Scholar
  5. Bellinger D, Leviton A, Waternaux C, Needleman H, Rabinowitz M. Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. New England Journal of Medicine 316: 1037–1043, 1987PubMedCrossRefGoogle Scholar
  6. Bentur Y, Brook G, Behar R, Taitelman U. Meso-2,3-dimercaptosuccinic acid in the diagnosis and treatment of lead poisoning. Clinical Toxicology 25: 39–51, 1987PubMedCrossRefGoogle Scholar
  7. Cantilena LR, Klaassen CD. The effect of chelating agents on the excretion of endogenous metals. Toxicology and Applied Pharmacology 63: 344–350, 1982PubMedCrossRefGoogle Scholar
  8. Castellino N, Aloj S. Effects of calcium sodium ethylenediaminetetraacetate on the kinetics of distribution and excretion of lead in the rat. British Journal of Industrial Medicine 22: 172–180, 1965Google Scholar
  9. Centers for Disease Control. Preventing lead poisoning in young children. Department of Health and Human Services, Washington, DC, 1991Google Scholar
  10. Charney E, Kessler B, Farfel M, Jackson D. Childhood lead poisoning: a controlled trial of the effect of dust-control measures on blood lead levels. New England Journal of Medicine 309: 1089–1093, 1983PubMedCrossRefGoogle Scholar
  11. Chisolm JJ. The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. Journal of Pediatrics 73: 1–38, 1968PubMedCrossRefGoogle Scholar
  12. Cory-Slechta DA. Mobilization of lead over the course of DMSA chelation therapy and long-term efficacy. Journal of Pharmacology and Experimental Therapeutics 246: 84–91, 1988PubMedGoogle Scholar
  13. Cory-Slechta DA, Weiss B, Cox C. Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy. Journal of Pharmacology and Experimental Therapeutics 243: 804–813, 1987PubMedGoogle Scholar
  14. Domingo JL, Paternain JL, Llobet JM, Corbella J. Developmental toxicity of subcutaneously administered meso-2,3-dimercaptosuccinic acid in mice. Fundamental and Applied Toxicology 11: 715–722, 1988PubMedCrossRefGoogle Scholar
  15. Farfel MR, Chisolm JJ. An evaluation of experimental practices for abatement of residential lead-based paint: report on a pilot project. Environmental Research 55: 199–212, 1991PubMedCrossRefGoogle Scholar
  16. Forbes GB, Woodruff CW (Eds). Pediatric nutrition handbook, 2nd ed., American Academy of Pediatrics, Elk Grove Village, 1985Google Scholar
  17. Fournier L, Thomas G, Garnier R, Buisine A, Houze P, et al. 2,3-Dimercaptosuccinic acid treatment of heavy metal poisoning in humans. Medical Toxicology 3: 499–504, 1988PubMedGoogle Scholar
  18. Friedheim E, Corvi C, Wakker CH. Meso-dimercaptosuccinic acid a chelating agent for the treatment of mercury and lead poisoning. Journal of Pharmacy and Pharmacology 28: 711–712, 1976PubMedCrossRefGoogle Scholar
  19. Friedheim EAH, Da Salva JR, Martins AV. Treatment of schistosomiasis mansoni with antimony-a,a’-dimercapto-potassium succinate (TWSb). American Journal of Tropical Medicine and Hygiene 3: 714–727, 1954PubMedGoogle Scholar
  20. Friedheim E, Graziano JH, Popovac D, Dragovic D, Kaul B. Treatment of lead poisoning by 2,3-dimercaptosuccinic acid. Lancet 2: 1234–1236, 1978PubMedCrossRefGoogle Scholar
  21. Fulton M, Thomson G, Hunter R, Gillian R, Laxen D, Hepburn W. Influence of blood lead on the ability and attainment of children in Edinburgh. Lancet 1: 1222–1225, 1987Google Scholar
  22. Glotzer DE, Bauchner H. Management of childhood lead poisoning: a survey. Pediatrics 89: 614–618, 1992PubMedGoogle Scholar
  23. Graziano JH. Role of 2,3-dimercaptosuccinic acid in the treatment of heavy metal poisoning. Medical Toxicology 1: 155–162, 1986PubMedGoogle Scholar
  24. Graziano JH, Cuccia D, Friedheim E. The pharmacology of 2,3-dimercaptosuccinic acid and its potential use in arsenic poisoning. Journal of Pharmacology and Experimental Therapeutics 207: 1051–1055, 1978aPubMedGoogle Scholar
  25. Graziano JH, Leong JK, Friedheim E. 2,3-dimercaptosuccinic acid: a new agent for the treatment of lead poisoning. Journal of Pharmacology and Experimental Therapeutics 206: 696–700, 1978bPubMedGoogle Scholar
  26. Graziano JH, LoIacono NJ, Meyer P. Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. Journal of Pediatrics 113: 751–757, 1988PubMedCrossRefGoogle Scholar
  27. Graziano JH, LoIacono NJ, Moulton T, Mitchell ME, Slavkovich V, Zarate C. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication. Journal of Pediatrics 120: 133–139, 1992PubMedCrossRefGoogle Scholar
  28. Graziano JH, Siris ES, LoIacono N, Silverg SJ, Turgeon L. 2,3-Dimercaptosuccinic acid as an antidote for lead intoxication. Clinical Pharmacology and Therapeutics 37: 431–438, 1985PubMedCrossRefGoogle Scholar
  29. Hammond PB. The effects of chelating agents on the tissue distribution and excretion of lead. Toxicology and Applied Pharmacology 18: 296–310, 1971PubMedCrossRefGoogle Scholar
  30. Hammond PB. The effects of D-penicillamine on the tissue distribution and excretion of lead. Toxicology and Applied Pharmacology 26: 241–246, 1973PubMedCrossRefGoogle Scholar
  31. Hammond PB, Aronson AL, Olson WC. The mechanism of mobilization of lead by ethylenediaminetetraacetate. Journal of Pharmacology and Experimental Therapeutics 157: 196–206, 1967PubMedGoogle Scholar
  32. Haust HL, Inwood M, Spence JD, Poon HC, Peter F. Intramuscular administration of iron during long-term chelation therapy with 2,3-dimercaptosuccinic acid in a man with severe lead poisoning. Clinical Biochemistry 22: 189–196, 1989PubMedCrossRefGoogle Scholar
  33. Jugo S, Maljkovic T, Kostial K. Influence of chelating agents on the gastrointestinal absorption of lead. Toxicology and Applied Pharmacology 34: 259–263, 1975PubMedCrossRefGoogle Scholar
  34. Kapoor SC, Wielopolski L, Graziano JH, LoIacono NJ. Influence of 2,3-dimercaptosuccinic acid on gastrointestinal lead absorption and whole-body lead retention. Toxicology and Applied Pharmacology 97: 525–529, 1989PubMedCrossRefGoogle Scholar
  35. Kostygov NM. The antidotal action of mercaptosuccinic acid and Unithiol against mercury. Farmakologiia i Toksikologiia 21: 64–69, 1958PubMedGoogle Scholar
  36. Needleman HL, Gatsonis CA. Low-level lead exposure and the IQ of children. Journal of the American Medical Association 263: 673–678, 1990PubMedCrossRefGoogle Scholar
  37. Perry HM, Perry EF. Normal concentrations of some trace metals in human urine: changes produced by ethylenediaminetetraacetate. Journal of Clinical Investigation 38: 1452–1463, 1959PubMedCrossRefGoogle Scholar
  38. Shannon M, Graef J, Lovejoy FH. Efficacy and toxicity of D-penicillamine in low-level lead poisoning. Journal of Pediatrics 112: 799–804, 1988PubMedCrossRefGoogle Scholar
  39. Stremski ES, Fifield GC, Jagodzinski MA. Dimercaptosuccinate (DMSA) as chelation agent for children with low level lead toxicity: an open pilot trial. Abstract. American Journal of Diseases of Childhood 146: 482–483, 1992Google Scholar
  40. Thomas DJ, Chisolm JJ. Lead, zinc and copper decorporation during calcium disodium ethylenediamine tetraacetate treatment of lead-poisoned children. Journal of Pharmacology and Experimental Therapeutics 239: 829–835, 1986PubMedGoogle Scholar
  41. Ting KS, Liang YI, Shi J, Chen W, Gu T, et al. Chelate stability of sodium dimercapto-succinate on the intoxications from many metals. Chinese Medical Journal 51: 304–307, 1965Google Scholar
  42. US Department of Health and Human Services. Succimer approved to treat severe lead poisoning in children. FDA Medical Bulletin 21: 5, 1991Google Scholar
  43. Wang S-C, Ting K-ST, Wu C-C. Chelating therapy with NA-DMS in occupational lead and mercury intoxications. Chinese Medical Journal 84: 437–439, 1965PubMedGoogle Scholar
  44. Xu Z-F, Jones MM. Comparative mobilization of lead by chelating agents. Toxicology 53: 277–288, 1988PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Deborah E. Glotzer
    • 1
  1. 1.Boston Childhood Lead Poisoning Prevention ProgramBoston City Hospital/Boston University School of MedicineBostonUSA

Personalised recommendations